Search

Gestational hypertension (PIH), especially pre-eclampsia (PE), is a common complication of pregnancy. This condition poses significant risks to the health of both the mother and the fetus. Emerging evidence suggests that epigenetic modifications, particularly DNA methylation, may play a role in initiating the earliest pathophysiology of PIH. This article describes the relationship between DNA methylation and placental trophoblast function, genes associated with the placental microenvironment, the placental vascular system, and maternal blood and vascular function, abnormalities of umbilical cord blood and vascular function in the onset and progression of PIH, as well as changes in DNA methylation in the progeny of PIH, in terms of maternal, fetal, and offspring. We also explore the latest research on DNA methylation-based early detection, diagnosis and potential therapeutic strategies for PIH. This will enable the field of DNA methylation research to continue to enhance our understanding of the epigenetic regulation of PIH genes and identify potential therapeutic targets. [ABSTRACT FROM AUTHOR]

This document is a correction notice for an article titled "DNA methylation landscape in pregnancy-induced hypertension: progress and challenges." The authors reported an error in the affiliations of three authors during the proofing stage, and the correct affiliation has been added back to the article. The original article has been updated accordingly. The publisher, Springer Nature, remains neutral regarding jurisdictional claims and institutional affiliations. The authors of the article are Fengying Deng, Jiahui Lei, Junlan Qiu, Chenxuan Zhao, Xietong Wang, Min Li, Miao Sun, Meihua Zhang, and Qinqin Gao. [Extracted from the article]